Induction of thymidine phosphorylase expression by taxol does not enhance furtulon sensitivity in a cisplatin-resistant human ovarian carcinoma cell line

Anticancer Research

Volumn 23, Issue 2 B, 2003, Pages 1525-1531

  Hata, Kohkichi ^a   Osaki, Mitsuhiko ^b   Kanasaki, Haruhiko ^a   Nakayama, Kentaro ^a   Fujiwaki, Ritsuto ^a   Ito, Hisao ^b   Miyazaki, Kohji ^a  

^a SHIMANE UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

Author keywords

Cisplatin resistant human ovarian carcinoma cell line; Drug sensitivity; Furtulon; Taxol; Thymidine phosphorylase

Indexed keywords

CISPLATIN; DOXIFLURIDINE; PACLITAXEL; THYMIDINE PHOSPHORYLASE;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL CLONE; CELL GROWTH; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EXPOSURE; DRUG SENSITIVITY; EVALUATION; FUNCTIONAL ASSESSMENT; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; NITROBLUE TETRAZOLIUM TEST; NUCLEOTIDE SEQUENCE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOTRANSFORMATION; BLOTTING, WESTERN; CARCINOMA; CELL DIVISION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; ENZYME INDUCTION; FEMALE; FLOXURIDINE; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; PRODRUGS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; THYMIDINE PHOSPHORYLASE; TUMOR CELLS, CULTURED;

EID: 0037562605     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Kono A, Hara Y, Sugata S, Karube Y, Matsushima Y and Ishitsuka H: Activation of 5′-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors. Chem Pharma Bull 31: 175-178, 1983.
2. Scanlon KJ, Newman EM, Lu Y and Priest DG: Biochemical basis for cisplatinum and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 83: 8923-8925, 1986.
3. Berne M, Gustavsson B, Almersjo O, Spears P and Sundstrom E: Inhibition of thymidylate synthase after administration of doxifluridine in a transplantable colon carcinoma in the rat. Cancer Invest 6: 377-383, 1988.
4. de Graeff A, van Hoef ME, Tjia P, Heintz AP and Neijt JP: Continuous infusion of 5-fluorouracil in ovarian cancer patients refractory to cisplatin and carboplatin. Ann Oncol 2: 691-692, 1991.
5. Panici PB, Greggi S, Scambia G, Salerno MG, Baiocchi G, Cento R and Mancuso S: Mitomycin C and 5-fluorouracil salvage chemotherapy in platinum-resistant ovarian carcinoma. Oncology 49: 183-187, 1992.
6. Hempling RE, Piver MS, Baker TR and O'Neill Mullen C: Lack of activity of 5-fluorouracil plus mitomycin-C as salvage therapy in cisplatin-resistant epithelial ovarian cancer: results of a phase II trial. Eur J Gynaecol Oncol 15: 165-169, 1994.
7. Long III HJ, Nelimark RA, Su JQ, Garneau SC, Levitt R, Goldberg RM, Poon MA and Kugler JW: Phase II evaluation of 5-fluorouracil and low-dose leucovorin in cisplatin-refractory advanced ovarian carcinoma. Gynecol Oncol 54: 180-183, 1994.
8. Kamphuis JT, Huider HC, Ras GJ, Verhagen CAH, Katemen I, Vreeswijk JHA and Burghouts JTM: High-dose 5-fluorouracil and leucovorin as second-line chemotherapy in patients with platinum-resistant epithelial ovarian cancer. Cancer Chemother Pharmacol 37: 190-192, 1995.
9. Scanlon KJ and Kashani-Sabet M: Elevated expression of thymidylate synthase cycle genes in cisplatin-resistant human ovarian carcinoma A2780 cells. Proc Natl Acad Sci USA 85: 650-653, 1988.
10. Hill BT, Shellard SA, Hosking LK, Dempke WC, Fichtinger-Schepman AM, Tone T, Scanlon KJ and Whelan RD: Characterization of a cisplatin-resistant human ovarian carcinoma cell line expressing cross-resistance to 5-fluorouracil but collateral sensitivity to methotrexate. Cancer Res 52: 3110-3118, 1992.
11. Chu E, Lai GM, Zinn S and Alleqra CL: Resistance of a human ovarian cancer line to 5-fluorouracil associated with decreased levels of 5-fluorouracil in DNA. Mol Pharmacol 38: 410-417, 1990.
12. Chung YM, Park S-H, Park JK, Kim Y-T, Kang Y-K and Yoo YD: Establishment and charaterization of 5-fluorouracil-resistant gastric cancer cells. Cancer Lett 159: 95-101, 2000.
13. Yamamoto K, Kikuchi Y, Kudoh K and Nagata I: Modulation of cisplatin sensitivity by taxol in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. J Cancer Res Clin Oncol 126: 168-172, 2000.
14. Hata K, Kamikawa T, Arao S, Tashiro H, Katabuchi H, Okamura H, Fujiwaki R and Miyazaki K: Expression of the thymidine phosphorylase gene in epithelial ovarian cancer. Br J Cancer 79: 1848-1854, 1999.
15. Hata K, Fujiwaki R, Nakayama K, Fukumoto M and Miyazaki K: Expression of TP and TIE2 genes in normal ovary with corpus luteum and in ovarian cancer; correlation with ultrasound-derived peak systolic velocity. Mol Hum Reprod 6: 319-323, 2000.
16. Fujiwaki R, Hata K, Nakayama K, Fukumoto M and Miyazaki K: Thymidylate synthase expression in epithelial ovarian cancer: relationship with thymidine phosphorylase expression and prognosis. Oncology 59: 152-157, 2000.
17. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T and Ishitsuka H: Induction of thymidine phosphorylase activity and enhancement of Capecitabine efficacy by Taxol/Taxotere in human cancer xenografts. Clin Cancer Res 4: 1013-1019, 1998.